(Total Views: 612)
Posted On: 08/22/2021 4:41:55 PM
Post# of 149194
I guess I was confused by this statement on the interim analysis:
Preliminary Interim Task 1 Report:
Pre-Analysis of mTNBC from Trial 756 (Compassionate Use) and Trial 706 (mTNBC)
▪ Goal of Interim Analysis is to compare PFS and OS in relation to
Standard of Care (SOC) or Sacituzumab Govitecan (SG) Trial
▪ Goal one: Have a mPFS >2.3 (SOC) or >5.6 (SG)
▪ Goal two: Have a mOS >6.7 (SOC) or >12.1 (SG)
Notice that mOS is nowhere mentioned in the outcomes.
Preliminary Interim Task 1 Report:
Pre-Analysis of mTNBC from Trial 756 (Compassionate Use) and Trial 706 (mTNBC)
▪ Goal of Interim Analysis is to compare PFS and OS in relation to
Standard of Care (SOC) or Sacituzumab Govitecan (SG) Trial
▪ Goal one: Have a mPFS >2.3 (SOC) or >5.6 (SG)
▪ Goal two: Have a mOS >6.7 (SOC) or >12.1 (SG)
Notice that mOS is nowhere mentioned in the outcomes.
(0)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
